Vitrification at the germinal vesicle stage does not affect the methylation profile of H19 and KCNQ1OT1 imprinting centers in human oocytes subsequently matured in vitro

Al-Khtib, Mohamed; Perret, Astrid; Khoueiry, Rita; Ibala-Romdhane, Samira; Blachère, Thierry; Grèze, Cécile; Lornage, Jacqueline; Lefèvre, Annick

doi:10.1016/j.fertnstert.2011.02.029

Cited by 49 publications

(33 citation statements)

References 34 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During vitrification, immature oocytes are cryopreserved under special conditions to avoid cryodamage to cytoplasm, nucleus and gene expression, and to maintain their development potential. The recovery of nuclear and cytoplasmic organelles from vitrification determined the developmental competence of oocytes [28] . In our study, immature oocytes lacked the surrounding granulosa cells, and the rate of maturation with or without vitrification was similar (78.3 and 72.4%, respectively), which indicates that the maturation rates were not significantly affected when oocytes were vitrified at immature GV, followed by IVM.…”

Section: Discussionmentioning

confidence: 99%

“…Low temperatures and exposure to the cryoprotectant agent could also lead to a high abnormal spindle and chromosome rate in MII oocytes [30] . The chromosomes are protected within the membrane, and no microtubular structure has formed yet at the GV stage [28,30] . We expected that oocytes cryopreserved at the GV stage would show more stability against cryoinjury to spindle.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ultrastructural Changes and Methylation of Human Oocytes Vitrified at the Germinal Vesicle Stage and Matured in vitro after Thawing

Liu

Zhou

Chu

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aim: The study aimed to assess the effect of in vitro vitrification and maturation on the nuclear configuration, cytoplasmic maturation and global DNA methylation pattern of human germinal vesicle (GV) stage oocytes. Methods: Human oocytes from infertile women were randomly assigned to one of 3 groups: (i) metaphase II (MII) oocytes matured in vivo (vivo-MII, n = 56) as controls; (ii) MII oocytes matured in vitro (vitro-MII, n = 106); and (iii) MII oocytes that were vitrified at the GV stage, warmed and matured in vitro (cryo-MII, n = 122). All MII oocytes were fixed and immunofluorescence staining for spindle, chromosome, mitochondrion and cortical granules (CGs) were performed; examination was done using immunofluorescence laser scanning confocal microscope. The expression of 5-methycytosine in these MII oocytes was also assessed. Results: No significant difference was observed between vitro-MII and cryo-MII groups with respect to oocyte maturation rate (72.4 vs. 78.3%). No significant differences were observed in the distribution of mitochondria, migration of CG and global DNA methylation pattern among the 3 study groups. However, the abnormal configuration of spindle and chromosome was significantly higher in cryo-MII group (78.9 and 84.2%) as compared to that in the vitro-MII (45.0 and 50.0%, p < 0.05) and vivo-MII groups (27.3 and 36.4%, p < 0.05). Conclusion: GV oocytes appeared to resist vitrification and retain their potential for maturation to MII stage oocytes after thawing. However, GV oocytes vitrification combined with in vitro maturation could affect the organization of spindle and chromosome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ultrastructural Changes and Methylation of Human Oocytes Vitrified at the Germinal Vesicle Stage and Matured in vitro after Thawing

Liu

Zhou

Chu

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Some studies have demonstrated that vitrification does not significantly alter gene methylation patterns in oocytes [110,115,119] and blastocysts [112]. In contrast, vitrification has been found to reduce gene methylation in mouse oocytes [113], embryos [112], and fetuses [117].…”

Section: Molecular Effects Of Cryopreservationmentioning

confidence: 99%

Cryopreservation of mammalian oocytes and embryos: current problems and future perspectives

Moussa

Shen

Zhang

et al. 2014

Sci. China Life Sci.

View full text Add to dashboard Cite

Cryopreservation techniques for mammalian oocytes and embryos have rapidly progressed during the past two decades, emphasizing their importance in various assisted reproductive technologies. Pregnancies and live births resulting from cryopreserved oocytes and embryos of several species including humans have provided proof of principle and led to the adoption of cryopreservation as an integral part of clinical in vitro fertilization. Considerable progress has been achieved in the development and application of the cryopreservation of mammalian oocytes and embryos, including preservation of the reproductive potential of patients who may become infertile, establishment of cryopreserved oocyte banks, and transport of oocytes and embryos internationally. However, the success rates are still far lower than those obtained with fresh oocytes and embryos, and there are still obstacles that need to be overcome. In this review, we address the major obstacles in the development of effective cryopreservation techniques. Such knowledge may help to eliminate these hurdles by revealing which aspects need improvement. Furthermore, this information may encourage further research by cryobiologists and increase the practical use of cryopreservation as a major part of assisted reproductive technologies for both humans and animal species. cryopreservation, mammals, oocytes, embryos, cryoinjuries Citation:Moussa M, Shu J, Zhang XH, Zeng FY. Cryopreservation of mammalian oocytes and embryos: current problems and future perspectives. Sci China Life Sci, 2014, 57: 903 -914,

show abstract

“…Unless noted otherwise, all studies discussed herein are in human. Table 2 summarizes the ranges of values obtained from a total of 23 studies that cryopreserved human oocytes at the GV stage, 14 and 12 of which used slow-freezing or vitrification protocols, respectively (Mandelbaum et al, 1988;Toth et al, 1994a;Toth et al, 1994b;Baka et al, 1995;Son et al, 1996;Park et al, 1997;Chung et al, 2000;Goud et al, 2000;Wu et al, 2001;Boiso et al, 2002;Chen et al, 2004;Fuchinoue et al, 2004;Isachenko et al, 2006;Cao et al, 2009;Fasano et al, 2010;Al-Khtib et al, 2011;Combelles et al, 2011;Criado et al, 2011;Liu et al, 2011;Versieren et al, 2011;Zhang et al, 2011;Fasano et al, 2012;Wang et al, 2012). Seventy percent (16/23) of studies evaluated the in vitro developmental competence of cryopreserved GV oocytes based on fertilization, cleavage, and in some instances even blastocyst formation.…”

Section: Advantages and Drawbacks Of Cryopreserving Immature Oocytes mentioning

confidence: 99%

“…Studies should undoubtedly continue to evaluate spindles and chromosomes; however, assessment should be expanded to include a panel of measures, among which may be DNA damage, gene expression (Monzo et al, 2012), oocyte physiology (Gardner et al, 2007), and organelle function such as integrity of the endoplasmic reticulum (Lowther et al, 2009), as reported in cryopreserved in vivo matured oocytes. One step in a promising direction pertains to a recent confirmation that the methylation profiles of two imprinting control regions did not change with vitrification at the GV stage followed by IVM (Al-Khtib et al, 2011).…”

Section: Cellular and Molecular Evaluationsmentioning

confidence: 99%

The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges

Combelles¹,

Chateau²

2012

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Improved oncological treatments permit increased survival rates, although cancer patients remain at risk of losing ovarian function. An attractive option for fertility preservation includes the use of immature oocytes, a strategy which can occur on a rapid timeline and without hormonal stimulation. As a result, cancer therapy can proceed promptly even in patients with hormone-sensitive tumors. Following retrieval, immature oocytes can be cryopreserved at either the immature germinal vesicle or the mature metaphase-II stage, i.e. either before or after in vitro maturation (IVM). We present a critical review of previous human studies on the cryopreservation of immature oocytes. Evaluations include in vitro developmental competence upon thawing/warming, or organization of the spindle and chromosomes. Reported successes vary, perhaps in relation to the source of the oocytes and protocols for cryopreservation and IVM. Weaknesses exist with the experimental designs implemented to date, so caution must be exercised before considering the use of immature oocytes to be a safe and reliable practice in the fertility preservation of cancer patients. To date, results indicate that with current protocols, it may be best to cryopreserve immature oocytes after IVM at the metaphase-II stage. Nonetheless, efficacy remains very low. Future efforts should tailor and optimize not only cryopreservation, but also IVM protocols for use in either germinal vesicle or metaphase-II oocytes, together with a comprehensive assessment of oocyte function and developmental competence to term. Despite current challenges, the burgeoning field of immature oocyte cryopreservation constitutes a promising option for cancer patients with impaired ovarian function. KEY WORDS: immature oocyte, fertility preservation, cryopreservation, cancer, in vitro maturation Why target immature oocytes in cancer patients?In the last few decades, the incidence of cancer and the likelihood of survival have risen across the globe. A little over 1 in 3 women in North America are diagnosed with cancer every year. This constitutes an overwhelming number of young women of reproductive age undergoing chemotherapy, radiotherapy, and other oncologic treatments; an estimated 9% of cancer survivors are 20-39 years old in the United States. Invasive cancers are treated aggressively through chemotherapy, radiotherapy and surgeries to remove cancerous cells and masses. Unfortunately such treatments create irreversible damage to the gonads and possible sterility (reviewed by Anchan and Ginsburg, 2010). Depending on the type and dose, oncological therapies may result in damage and/or loss of not only germ cells but also the supporting somatic compartments of the ovarian follicle. Due to the women's finite number of oocytes and the irreplaceable nature of the pool Int. J. Dev. Biol. 56: 919-929 (2012)

show abstract

Vitrification at the germinal vesicle stage does not affect the methylation profile of H19 and KCNQ1OT1 imprinting centers in human oocytes subsequently matured in vitro

Cited by 49 publications

References 34 publications

Ultrastructural Changes and Methylation of Human Oocytes Vitrified at the Germinal Vesicle Stage and Matured in vitro after Thawing

Ultrastructural Changes and Methylation of Human Oocytes Vitrified at the Germinal Vesicle Stage and Matured in vitro after Thawing

Cryopreservation of mammalian oocytes and embryos: current problems and future perspectives

The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges

Contact Info

Product

Resources

About